Autoimmune pancreatitis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) No edit summary |
Iqra Qamar (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Patients should be managed appropriately and timely with [[glucocorticoids]] and immunomodulatory drugs to prevent complications such as pancreatic insufficiency, diabetes, and pancreatic calcifications or stones. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
* | * Patients should be managed appropriately and timely with glucocorticoids and immunomodulatory drugs to prevent complications such as: | ||
** Pancreatic insufficiency | |||
** Diabetes | |||
** | ** Pancreatic calcifications or stones | ||
** | |||
** | |||
==References== | ==References== | ||
Revision as of 17:33, 5 January 2018
|
Autoimmune pancreatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Autoimmune pancreatitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Autoimmune pancreatitis secondary prevention |
|
Risk calculators and risk factors for Autoimmune pancreatitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Iqra Qamar M.D.[2]
Overview
Patients should be managed appropriately and timely with glucocorticoids and immunomodulatory drugs to prevent complications such as pancreatic insufficiency, diabetes, and pancreatic calcifications or stones.
Secondary Prevention
- Patients should be managed appropriately and timely with glucocorticoids and immunomodulatory drugs to prevent complications such as:
- Pancreatic insufficiency
- Diabetes
- Pancreatic calcifications or stones